New military funding for Neuren's brain injury drug
This article was originally published in Scrip
Executive Summary
Neuren Pharmaceuticals is to receive $5.5 million in new funding from the US military to support a planned Phase II trial with its neuroprotectant for traumatic brain injury (TBI) NNZ-2566.